London, UK; Brentwood, TN, US; 26 November 2007 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, announces that, on 23 November 2007, the following options over ordinary shares of 2 pence each in Protherics (“Ordinary Shares”) were granted under the terms of the Company’s Long Term Incentive Plan:
